Absci Corp (ABSI)
4.995
+0.20
(+4.28%)
USD |
NASDAQ |
May 22, 10:48
Absci Cash from Operations (TTM): -62.38M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -62.38M |
December 31, 2023 | -64.64M |
September 30, 2023 | -68.28M |
June 30, 2023 | -76.96M |
March 31, 2023 | -80.31M |
December 31, 2022 | -81.34M |
September 30, 2022 | -79.85M |
Date | Value |
---|---|
June 30, 2022 | -82.55M |
March 31, 2022 | -74.46M |
December 31, 2021 | -60.60M |
September 30, 2021 | -46.04M |
June 30, 2021 | -27.00M |
March 31, 2021 | -15.83M |
December 31, 2020 | -10.97M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-82.55M
Minimum
Jun 2022
-10.97M
Maximum
Dec 2020
-59.37M
Average
-66.46M
Median
Cash from Operations (TTM) Benchmarks
Eli Lilly and Co | 3.676B |
Recursion Pharmaceuticals Inc | -316.76M |
Creative Medical Technology Holdings Inc | -5.083M |
CytomX Therapeutics Inc | -91.43M |
HOOKIPA Pharma Inc | -78.83M |